On the 13th of December AstraZeneca announced the acquisition of rare disease specialist Alexion. The deal, worth 15 billion USD, capped a busy year for AstraZeneca during which the development of its vaccine with Oxford University had temporarily made it the most valuable FTSE 100 company. After the deal, Alexion’s shareholders now own 15 percent…

Read More

This year has seen a significant rise in digitalisation across almost every sector, with the pandemic acting as a catalyst for change in communication and innovation methods. There has been a universal acceleration of technology adoption throughout the world, and the health sector has certainly not been an exception. While a general sense of transformation…

Read More

The vaccine breakthrough has triggered widespread hopes of a return to normality by spring and a sharp revival in global markets (Figure 1). For Big Pharma, it is also a moment of justification that could redefine the previously undervalued industry.   Figure 1: Stock Markets Bounce Back. Refinitiv.   As recently as 2009-10, pharmaceutical companies’…

Read More

Drug makers have long been viewed unfavourably by the public, with the pharmaceutical industry being rated the most hated industry in the US according to a 2019 poll by Gallup, an analytics company known for public opinion polls (see Figure 1). Historically, companies have been blamed for charging extortionate prices for life-changing drugs, as well…

Read More

Amazon has been one of the most innovative and disruptive companies of this century, with astonishing success in almost all areas of online retail. Originally a bookselling company, Amazon’s product portfolio is extensive and its new ambitious plan to expand into healthcare and the prescription drug market represents the largest and most prominent unchartered territory…

Read More